AVIGI
✽ AVIGI Therapeutics · Leiden, NL

Upstream of
Kidney Disease.

AVIGI is developing VL166 — a first-in-class covalent heparanase inhibitor designed to protect the kidney's filter, not just manage the symptoms.

See the science →Our program
Approach
First-in-class, covalent heparanase inhibition
Lead program
Diabetic & rare kidney disease
Stage
Preclinical proof of concept
✽ See it lock on

VL166 inside heparanase,
atom by atom.

The enzyme that drives kidney disease, captured in a 1.52 Å crystal structure with our covalent inhibitor bound. PDB 7PR7.

Open the walkthrough →